Prelude Therapeutics宣布，其针对PRT13722的研究性新药（IND）申请已获得美国食品药品监督管理局（FDA）的批准。该药物为该公司研发的同类首创（first-in-class）口服KAT6A选择性降解剂。这一监管许可标志着该候选药物向临床开发阶段迈出了关键一步，有望为特定癌症患者群体带来新的治疗选择。
Prelude Therapeutics宣布，其针对PRT13722的研究性新药（IND）申请已获得美国食品药品监督管理局（FDA）的批准。该药物为该公司研发的同类首创（first-in-class）口服KAT6A选择性降解剂。这一监管许可标志着该候选药物向临床开发阶段迈出了关键一步，有望为特定癌症患者群体带来新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.